Hepion Pharmaceuticals (HEPA) News Today → What’s Really Next for America… (From Porter & Company) (Ad) Free HEPA Stock Alerts $1.19 -0.07 (-5.56%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 7, 2024 | americanbankingnews.comHepion Pharmaceuticals (NASDAQ:HEPA) Shares Down 5.5% April 28, 2024 | nytimes.comU.S. Lags Behind Other Countries in Hepatitis-C TreatmentApril 22, 2024 | finance.yahoo.comWhy Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?April 22, 2024 | investorplace.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 22, 2024 | investorplace.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 21, 2024 | stockhouse.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialApril 20, 2024 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialApril 19, 2024 | marketwatch.comHepion Pharma to Wind-Down Phase 2b Ascend-NASH Trial, Cites Resource ConstraintsApril 19, 2024 | marketwatch.comHepion Pharma Shares Plunge 31% After Disclosing Plans to Wind Down TrialApril 19, 2024 | finance.yahoo.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialApril 19, 2024 | marketbeat.comTrading was temporarily halted for "HEPA" at 04:04 PM with a stated reason of "News pending."April 19, 2024 | globenewswire.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' TrialApril 17, 2024 | msn.comHEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023April 14, 2024 | morningstar.comHepion Pharmaceuticals Inc HEPAMarch 24, 2024 | investing.comHepion Pharmaceuticals Inc (HEPA)March 6, 2024 | globenewswire.comHepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael PurcellFebruary 16, 2024 | finance.yahoo.comHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsFebruary 16, 2024 | globenewswire.comHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsJanuary 3, 2024 | finance.yahoo.comHepion Pharmaceuticals to Present at NASH-TAG 2024December 7, 2023 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesDecember 7, 2023 | realmoney.thestreet.comHepion Pharmaceuticals downgraded to Hold from Buy at BrooklineDecember 7, 2023 | marketwatch.comHepion Sets Restructuring; To Explore Strategic OptionsDecember 7, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesDecember 7, 2023 | marketbeat.comTrading was temporarily halted for "HEPA" at 07:12 AM with a stated reason of "News pending."November 28, 2023 | finance.yahoo.comHepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitNovember 28, 2023 | msn.comHepion Pharmaceuticals says Wijngaard buys 5K shares in coNovember 13, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseNovember 10, 2023 | benzinga.comHepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of RencofilstatNovember 10, 2023 | finance.yahoo.comHepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatOctober 31, 2023 | money.usnews.comGSK Signs $1 Billion Deal for Exclusive License to J&J's Hepatitis B TherapyOctober 25, 2023 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer ModelOctober 25, 2023 | finance.yahoo.comHepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer ModelOctober 13, 2023 | marketbeat.comTrading was temporarily halted for "HEPA" at 02:10 PM with a stated reason of "LULD pause."September 29, 2023 | msn.comHepion to sell $5M in shares through registered direct offeringSeptember 29, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq RulesSeptember 21, 2023 | finance.yahoo.comHepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare ConferenceSeptember 21, 2023 | finance.yahoo.comNew Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening ProgramSeptember 19, 2023 | finance.yahoo.comHere's Why Hepion Pharmaceuticals (NASDAQ:HEPA) Must Use Its Cash WiselySeptember 19, 2023 | finance.yahoo.comHepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver CancerSeptember 18, 2023 | finance.yahoo.comInsider Buying: Robert Foster Acquires 1,600 Shares of Hepion Pharmaceuticals IncSeptember 14, 2023 | finance.yahoo.comRencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary FibrosisSeptember 7, 2023 | msn.comHepion Pharmaceuticals' CMO Todd Hobbs resignsSeptember 6, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces Management ChangesSeptember 6, 2023 | finance.yahoo.comWall Street Analysts Think Hepion Pharmaceuticals, Inc. (HEPA) Could Surge 674.09%: Read This Before Placing a BetAugust 16, 2023 | finance.yahoo.comHEPA - Hepion Pharmaceuticals, Inc.July 25, 2023 | seekingalpha.comHEPA Hepion Pharmaceuticals, Inc.June 15, 2023 | finance.yahoo.comHepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023May 24, 2023 | finance.yahoo.comHepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical SciencesMay 24, 2023 | finance.yahoo.comHere's Why Hepion Pharma (HEPA) is Up More Than 80% in Two DaysMay 22, 2023 | msn.comWhy Hepion Pharmaceuticals Stock Is Soaring Monday Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Email Address The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 HEPA Media Mentions By Week HEPA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HEPA News Sentiment▼1.280.57▲Average Medical News Sentiment HEPA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HEPA Articles This Week▼21▲HEPA Articles Average Week Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ASLN News CANF News TRVN News VCNX News TENX News CMMB News KTTA News ADXS News CYCN News CVKD News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HEPA) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
